Why is monitoring for bleeding and anaemia recommended when sofosbuvir + velpatasvir is taken with dabigatran etexilate?

When Sofosbuvir/Velpatasvir Gilead is taken with dabigatran etexilate, monitoring for bleeding and anaemia is recommended because dabigatran exposure is expected to increase, raising bleeding risk; although the interaction has not been studied, a coagulation test helps identify patients at increased risk.